If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-25. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Vestigiality, adaptionist and reproductive views === Whether the clitoris is vestigial, an adaptation, or serves a reproductive function has been debated. Geoffrey Miller stated that Helen Fisher, Meredith Small and Sarah Blaffer Hrdy "have viewed the clitoral orgasm as a legitimate adaptation in its own right, with major implications for female sexual behavior and sexual evolution". Like Lynn Margulis and Natalie Angier, Miller believes, "The human clitoris shows no apparent signs of having evolved directly through male mate choice. It is not especially large, brightly colored, specifically shaped or selectively displayed during courtship". He contrasts this with other female species that have clitorises as long as their male counterparts. He said the human clitoris "could have evolved to be much more conspicuous if males had preferred sexual partners with larger brighter clitorises" and that "its inconspicuous design combined with its exquisite sensitivity suggests that the clitoris is important not as an object of male mate choice, but as a mechanism of female choice".
Otto Knut Olof Folin (April 4, 1867 – October 25, 1934) was a Swedish-born American chemist who is best known for his groundbreaking work at Harvard University on practical micromethods for the determination of the constituents of protein-free blood filtrates and the discovery of creatine phosphate in muscles.
The authors hypothesized that the higher levels of CD8+ T cell infiltration was due to anti-CTLA-4 inhibited the conversion of CD4 T cells to T regulator cells and further reduced T regulatory suppression with anti-PD-1. This combination promoted a more robust inflammatory response to the tumor that reduced the size of the cancer. Most recently, the FDA has approved a combination therapy with both anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) in October 2015. The molecular factors and receptors necessary making a tumor receptive to anti-PD1 treatment remains unknown. PD-L1 expression on the surface on cancer cells plays a significant role. PD-L1 positive tumors were twice as likely to respond to combination treatment. However patients with PD-L1 negative tumors also have limited response to anti-PD1, demonstrating that PD-L1 expression is not an absolute determinant of the effectiveness of therapy. Higher mutational burden in the tumor is correlated with a greater effect of the anti-PD-1 treatment. In clinical trials, patients who benefited from anti-PD1 treatment had cancers, such as melanoma, bladder cancer, and gastric cancer, that had a median higher average number of mutations than the patients who did not respond to the therapy. However, the correlation between higher tumor burden and the clinical effectiveness of PD-1 immune blockade is still uncertain. The 2018 Nobel Prize for Medicine was awarded to James P Allison and Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation".
==== Clinical trials ==== In terms of antimicrobial performance, studies report that the peptides found in DBHA can selectively kill microorganisms without significant toxicity to host cells. This is attributed to the presence of free protonated amines in G3KPCA, which interact with and disrupt negatively charged bacterial membranes, contributing to bactericidal activity. In vitro compatibility tests using mouse NIH-3T3 fibroblasts showed that DBHA is non-cytotoxic under the tested condition. DBHA has also been tested in more realistic conditions, including bleeding environments. When applied to porcine skin covered in blood, only minor differences were observed between wet and dry adhesion performance. It was also tested on tissues such as the stomach, heart, artery, and liver, where adhesion forces were measured. In rat incision models, DBHA was used in wound closure studies where closure was observed after seven days, in comparison to conventional sutures and commercial adhesives. Additional testing showed that after 24 hours in an adhesive conditioned medium, human dermal fibroblasts remained viable, indicating biocompatibility.
22 March – West Yorkshire Police launches an investigation into the alleged comments made about Diane Abbott by Conservative Party donor Frank Hester. A private member's bill introduced to Parliament by Conservative MP Gareth Johnson that aimed to prevent the expansion of London's Ultra Low Emission Zone runs out of Parliamentary time. Penny Mordaunt dismisses rumours of a potential leadership challenge against Rishi Sunak as "nonsense". MPs in the House of Commons give their backing to a private member's bill that will ban the import of hunting trophies into the UK if it becomes law. 24 March – Chancellor Jeremy Hunt says the Conservatives will keep the triple lock mechanism for deciding the rise in the state pension if they win the next election. 25 March – Former Conservative MP Scott Benton resigns his Parliamentary seat, triggering a by-election in the Blackpool South constituency. The UK formally accuses China of being behind a "malicious" cyberattack against MPs and the Electoral Commission. 26 March – Education Minister Robert Halfon and Armed Forces Minister James Heappey announce their resignations from the Sunak ministry, having decided to stand down from Parliament at the next election. BBC News reports that HM Treasury sent members of staff to work at Asian Infrastructure Investment Bank, which is accused of being "dominated" by the Chinese Communist Party. The first meeting of the East–West Council, established as part of the restoration of government in Northern Ireland, is held in London.
Sources: en.wikipedia.org
== Reception == Cry of Fear has received generally positive reviews, with reviewers praising its overall atmosphere and unique setting. Reviewers praised the game's story, atmosphere, tension, enemy designs, and inventory management, while some criticism was levied at the game's platforming segments and occasional crashes and bugs. Eric Sapp of IGN called the game "terrifying" and praised the addition of an inventory system with limited space similar to Resident Evil series for the decision making aspect. Antony Wright of SUPERJUMP named Cry of Fear "arguably the most disturbing and depraved horror title that I've ever played through" while also commending the game for sympathetically handling mature topics. Dennis Moiseyev and Destry Stutesman of The Gamer positively compared Cry of Fear to the Silent Hill series through its use of nightmare sequences, while employing a first-person perspective. Luke Plunkett of Kotaku opined that while the old engine made the game "a little janky" at times, the graphics and music in Cry of Fear were "genuinely tense". A review on Jeuxvideo.com praised the innovations to the GoldSrc engine, calling the improved the graphics and lighting in Cry of Fear unrecognized to Half-Life. Although acknowledging the technical limitations of an outdated engine, the music and "gloomy atmosphere" were also applauded by Jeuxvideo.com, stating the game proves "that a graphics engine, no matter how old it may be, can do some very beautiful things if it is used well".
== Earliest roots == Between around 3000 and 1200 BCE, the Ancient Egyptians and Mesopotamians made contributions to astronomy, mathematics, and medicine, which later entered and shaped Greek natural philosophy of classical antiquity, a period that profoundly influenced the development of what came to be known as biology.
== References == This article was submitted to WikiJournal of Medicine for external academic peer review in 2022 (reviewer reports). The updated content was reintegrated into the Wikipedia page under a CC-BY-SA-3.0 license (2023). The version of record as reviewed is: Maxim Masiutin, Maneesh Yadav, et al. (2023). "Alternative androgen pathways" (PDF). WikiJournal of Medicine. 10 (1): 3. doi:10.15347/wjm/2023.003. Wikidata Q100737840.
== Standards == A LIMS covers standards such as 21 CFR Part 11 from the Food and Drug Administration (United States), ISO/IEC 17025, ISO 15189, ISO 20387, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), FDA Food Safety Modernization Act (FSMA), HACCP, and ISBER Best Practices.
Fossil micro-organisms may have lived in hydrothermal vent precipitates from Quebec, soon after ocean formation during the Hadean, so the process appears to have been relatively rapid in terms of geological time.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.